ABT
Abbott Laboratories
$116.64
장중 · Vol 976.1K · 52주 $81.97–$137.49 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $110.77 · Aug 31, 2026
ABT 가격 추세
종가
$110.77
시가
$111.54
고가
$111.64
저가
$109.75
30초 브리핑
ABT 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 62%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 18.2배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 2.1배
평소보다 거래가 활발해 가격 움직임의 확인 강도가 높습니다.
2026-10-14
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
ABT 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
100 Abbott Park Road · Abbott Park, IL, United States · 직원 122,000명
시가총액
$190.97B
Trailing P/E
35.7
최근 12개월 이익 기준
Forward P/E
18.2
이익 증가 기대 반영
EPS (TTM)
$3.09
배당 수익률
2.24%
배당성향
79.0%
베타
0.58
시장보다 방어적
ROE
10.6%
P/B
3.74
EV/EBITDA
19.0
52주 범위
$81.97 – $137.49
현재 위치 62%
거래량
9.83M
20일 평균 4.68M · 2.1배
애널리스트 의견
매수 78%
총 27명 · 0m
DITM LEAPS Analysis
ABT 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT280317C00065000 | 3/17/28 · 1.5Y | $65.00 | $48.20 | 2.1x | 0.9077 | 5.9% | 7.47% | 46.42% | 26 | 85.33 | |
| ABT280121C00070000 | 1/21/28 · 1.4Y | $70.00 | $43.90 | 2.2x | 0.8910 | 8.1% | 7.29% | 45.64% | 252 | 85.09 | |
| ABT280121C00065000 | 1/21/28 · 1.4Y | $65.00 | $48.20 | 2.1x | 0.9057 | 5.9% | 7.47% | 48.91% | 37 | 84.99 | |
| ABT280317C00070000 | 3/17/28 · 1.5Y | $70.00 | $44.15 | 2.2x | 0.8885 | 8.6% | 8.38% | 44.99% | 282 | 84.54 | |
| ABT280317C00075000 | 3/17/28 · 1.5Y | $75.00 | $39.90 | 2.4x | 0.8734 | 11.4% | 7.52% | 41.44% | 12 | 79.61 | |
| ABT280121C00075000 | 1/21/28 · 1.4Y | $75.00 | $39.60 | 2.4x | 0.8697 | 10.7% | 9.60% | 43.98% | 22 | 79.01 | |
| ABT280121C00080000 | 1/21/28 · 1.4Y | $80.00 | $35.80 | 2.6x | 0.8469 | 15.2% | 9.50% | 42.04% | 147 | 77.07 | |
| ABT280121C00077500 | 1/21/28 · 1.4Y | $77.50 | $37.70 | 2.5x | 0.8585 | 12.8% | 9.55% | 43.04% | 10 | 76.35 | |
| ABT280317C00080000 | 3/17/28 · 1.5Y | $80.00 | $36.10 | 2.6x | 0.8461 | 15.9% | 10.53% | 41.25% | 45 | 75.37 | |
| ABT280317C00077500 | 3/17/28 · 1.5Y | $77.50 | $38.20 | 2.5x | 0.8572 | 14.0% | 9.42% | 42.27% | 3 | 74.70 | |
| ABT280121C00082500 | 1/21/28 · 1.4Y | $82.50 | $33.70 | 2.7x | 0.8348 | 17.3% | 10.68% | 40.97% | 76 | 74.19 | |
| ABT280121C00085000 | 1/21/28 · 1.4Y | $85.00 | $32.15 | 2.8x | 0.8185 | 21.1% | 11.51% | 41.16% | 370 | 72.17 | |
| ABT280317C00085000 | 3/17/28 · 1.5Y | $85.00 | $32.25 | 2.8x | 0.8188 | 21.4% | 13.95% | 40.30% | 199 | 70.99 | |
| ABT280317C00087500 | 3/17/28 · 1.5Y | $87.50 | $30.70 | 2.9x | 0.8062 | 25.5% | 11.73% | 39.09% | 378 | 69.45 | |
| ABT280121C00087500 | 1/21/28 · 1.4Y | $87.50 | $30.20 | 2.9x | 0.8055 | 24.3% | 11.92% | 39.94% | 89 | 68.24 | |
| ABT280121C00090000 | 1/21/28 · 1.4Y | $90.00 | $28.35 | 3.1x | 0.7918 | 28.2% | 11.64% | 38.67% | 333 | 66.92 | |
| ABT280317C00090000 | 3/17/28 · 1.5Y | $90.00 | $29.25 | 3.0x | 0.7901 | 30.4% | 11.97% | 38.98% | 207 | 65.06 | |
| ABT270917C00090000 | 9/17/27 · 1.0Y | $90.00 | $26.70 | 3.3x | 0.7923 | 23.8% | 13.48% | 40.38% | 1 | 62.29 | |
| ABT280121C00092500 | 1/21/28 · 1.4Y | $92.50 | $26.70 | 3.2x | 0.7744 | 33.1% | 13.48% | 38.52% | 153 | 61.79 | |
| ABT280317C00082500 | 3/17/28 · 1.5Y | $82.50 | $39.60 | 2.3x | 0.8094 | 29.6% | 8.08% | 53.21% | 5 | 61.25 |
재무제표
ABT 연간 손익·현금흐름·재무상태
매출 성장률
+5.7%
최근 연간 YoY
EPS 성장률
-51.3%
최근 연간 YoY
영업이익률
18.2%
최근 연간
FCF 마진
16.7%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $44.33B+5.7% | $41.95B+4.6% | $40.11B-8.1% | $43.65B |
| 매출총이익 | $25.01B+7.6% | $23.24B+5.0% | $22.13B-9.7% | $24.51B |
| 영업이익 | $8.05B+18.0% | $6.83B+5.4% | $6.48B-22.5% | $8.36B |
| 순이익 | $6.52B-51.3% | $13.40B+134.2% | $5.72B-17.5% | $6.93B |
| 희석 EPS | $3.72-51.3% | $7.64+134.4% | $3.26-16.6% | $3.91 |
| EBITDA | $12.07B+11.9% | $10.79B+2.3% | $10.54B-13.1% | $12.13B |
| 영업현금흐름 | $9.57B+11.8% | $8.56B+17.9% | $7.26B-24.2% | $9.58B |
| 잉여현금흐름 | $7.39B+16.4% | $6.35B+25.5% | $5.06B-35.2% | $7.80B |
| 총자산 | $86.71B+6.5% | $81.41B+11.2% | $73.21B-1.6% | $74.44B |
| 총부채 | $13.86B-7.7% | $15.02B-3.9% | $15.63B-11.8% | $17.72B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
ABT 실적·배당 일정
매출 하단
$12.90B
EPS 하단
$1.41
매출 상단
$13.16B
배당 지급일
2026-08-17
15일 전
실적 발표일
2026-10-14
D-43
EPS 상단
$1.44
매출 컨센서스
$12.99B
EPS 컨센서스
$1.42
배당락일
2026-07-15
48일 전
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jul 15, 2026 | $0.6300 |
| Apr 15, 2026 | $0.6300 |
| Jan 15, 2026 | $0.6300 |
| Oct 15, 2025 | $0.5900 |
| Jul 15, 2025 | $0.5900 |
| Apr 15, 2025 | $0.5900 |
| Jan 15, 2025 | $0.5900 |
| Oct 15, 2024 | $0.5500 |
뉴스
ABT 관련 최신 기사
제품·기술The Peer-Group Mispricing Sitting On BSX Stock
This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.
Trefis · Sep 1, 2026
제품·기술How Abbott Labs Is Embracing RFK Jr.'s Make America Healthy Again Movement
Abbott Laboratories is leaning into the Make America Healthy Movement, launching a new infant formula made with whole milk.
Investor's Business Daily · Aug 31, 2026
제품·기술What Is Abbott Laboratories (ABT) Telling Investors With Its New Infant Formula?
Abbott Laboratories (NYSE:ABT) launched Similac 360 Total Care Made With Whole Milk, a commercially sterile ready-to-feed liquid infant formula made with whole milk in the U.S. The product is the first of its kind in the U.S. market to combine whole milk with a ready-to-feed liquid format. The formula uses whole milk and a blend of human milk oligosaccharides to more closely mirror key elements of breast milk. The launch expands Abbott's infant nutrition portfolio and targets parents seeking...
Simply Wall St. · Aug 31, 2026
제품·기술Two Recessions Couldn’t Stop These 4 Healthcare Stocks From Raising Dividends
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can survive what comes next.
24/7 Wall St. · Aug 31, 2026
실적Why Is GE HealthCare (GEHC) Up 3.6% Since Last Earnings Report?
GE HealthCare (GEHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · Aug 28, 2026
- 제품·기술
Abbott wins CE mark for new LAA closure device
Abbott is aiming to capture share from Boston Scientific in the market for devices that seal the heart’s left atrial appendage to reduce stroke risk.
MedTech Dive · Aug 28, 2026
규제·법률FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the...
Benzinga · Aug 28, 2026
제품·기술Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.
Zacks · Aug 27, 2026
규제·법률The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.
24/7 Wall St. · Aug 27, 2026
제품·기술Has BSX Stock Fallen Far Enough To Buy?
U.S. electrophysiology growth slowed sharply and standalone WATCHMAN referrals declined in the same window, leaving the rest of Boston Scientific unable to maintain its growth-stock multiple.
Trefis · Aug 27, 2026
홀더
ABT 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
81.8%
기관 보유 (유동주식)
82.2%
내부자 보유
0.5%
기관 수
3,810
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 152.56M | $16.84B | 8.8% | 4.7% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 113.75M | $12.55B | 6.6% | 0.7% | Jun 30, 2026 |
| State Street Corporation | 80.93M | $8.93B | 4.7% | 1.7% | Jun 30, 2026 |
| Charles Schwab Investment Management, Inc. | 59.67M | $6.59B | 3.5% | 31.1% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 49.02M | $5.41B | 2.8% | 2.2% | Jun 30, 2026 |
| Geode Capital Management, LLC | 39.22M | $4.33B | 2.3% | 0.2% | Jun 30, 2026 |
| Capital Research Global Investors | 36.91M | $4.07B | 2.1% | -25.9% | Jun 30, 2026 |
| Capital International Investors | 34.65M | $3.82B | 2.0% | -7.6% | Jun 30, 2026 |
| Morgan Stanley | 26.61M | $2.94B | 1.5% | -11.6% | Jun 30, 2026 |
| NORGES BANK | 23.35M | $2.58B | 1.4% | -0.4% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.